Analysts see the shortened timeline and absence of an advisory committee meeting as positive signs for unrestricted approval. The FDA's eagerness to expand the label and transition from accelerated to traditional approval is evident in the expedited review timeline. This could set a precedent for other gene therapies seeking FDA approval, despite Elevidys not meeting its primary endpoint.
Sarepta Therapeutics' low P/S ratio reflects its poor revenue outlook. The market anticipates limited growth, hence the reduced stock price. Even a recent share price surge couldn't bring the P/S to industry median. A strong share price rise seems unlikely under these conditions.
Morning Movers Gapping up $星巴克(SBUX.US)$stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December. $諾和諾德(NVO.US)$stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
The promise for a bright 2024 comes after two years of abysmal performance of biopharma stocks. The S&P Biotechnology Select Industry Index surged 43% from its recent low in October 2023, reaching a new high since April 2022. Source: S&P A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
Analysts are bullish on Sarepta's future, predicting full U.S. approval. Strong demand for the therapy among eligible patients is also anticipated. The FDA is unlikely to withdraw the drug's accelerated approval and may expand Elevidys's label.
Investors are likely expecting limited future growth for Sarepta Therapeutics, reflected in the company's low P/S ratio. A continued weak growth forecast might hinder any sharp increase in its share price.
An overly optimistic 66% growth rate can delay Sarepta Therapeutics' profitability. Investing carries risks, considering the firm's high debt-to-equity ratio and current loss-making condition.
Sarepta Therapeutics股票討論區
專欄Today's Morning Movers and Top Ratings: GOOGL, AMD, TSLA, SBUX and More
Gapping up
$星巴克(SBUX.US)$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$諾和諾德(NVO.US)$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
專欄Several Biotech Stocks Have Been Hitting New Highs Since the Start of the Year, It's Biotech Industry Time to Shine
Source: S&P
A stable-to-improving environment characterized by falling inflation, low unemployment and the easing of hospital staffing pressures position medte...
🤫
T1 News halt
暫無評論